membrane-anchored tumor-targeted IL-12-armed T-cell therapy (The University of Texas MD Anderson Cancer Center)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namemembrane-anchored tumor-targeted IL-12-armed T-cell therapy (The University of Texas MD Anderson Cancer Center)
Drug Alias NameattIL-12 T-cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionVimentin modulatorsImmunostimulantsT lymphocytes stimulants
TargetsVimentin
Therapy Area/IndicationsSolid tumoursSarcomaOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsSolid tumoursSarcomaOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A